Trial: 201912136

A Phase Ib, open-label, dose-escalation study to evaluate the safety and pharmacokinetics of UTTR1147a in combination with standard of care in patients undergoing allogeneic hematopoietic stem cell transplantation

Phase

I (Cancer Control)

Principal Investigator

Pusic, Iskra

Disease Site

Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Myeloid and Monocytic Leukemia; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov